Skip to main content
. Author manuscript; available in PMC: 2015 Feb 6.
Published in final edited form as: BJU Int. 2011 Feb 14;108(8 0 2):E272–E277. doi: 10.1111/j.1464-410X.2010.09981.x

Table 2. Chemotherapeutic regimens.

Neoadjuvant chemotherapy (n = 24) Therapeutic chemotherapy (n = 17)


Regimen Receiving, n (%) Median cycles (range) Receiving, n (%) Median cycles (range)
Methotrexate, vinblastine, doxorubicin, cisplatin 5 (19) 4 (2–4) 3 (18) 4 (4–6)
Gemcitabine, cisplatin 19 (79) 4 (2–6) 4 (24) 5 (2–5)
Ifosfamide, paclitaxel, cisplatin 0 (0) – – 2 (12) 4.5 (4–5)
Doxorubicin, gemcitabine, ifosfamide, paclitaxel, cisplatin 0 (0) – – 3 (18) 4 (4–4)
Gemcitabine, cisplatin, paclitaxel 0 (0) – – 2 (12) 5.5 (5–6)
Gemcitabine, carboplatin, paclitaxel 0 (0) – – 2 (12) 5.5 (5–6)
Cyclophosphamide, docetaxel, doxorubicin 0 (0) – – 1 (6) 6 NA

NA, not available.